179 results about "Mucoproteins" patented technology

The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.

Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.

The present invention provides a variant of an immunoglobulin variable domain including (A) at least one CDR region and (B) framework regions flanking the CDR region, wherein the variant also contains (a) a CDR region having added or substituted therein at least on binding sequence and (b) the flanking framework regions, wherein the binding sequence is heterelogous to the CDR and is an antigenic sequence from a MUC-1 binding sequence.

The invention relates to the technical field of cosmetics for skin beautifying, and particularly relates to an application of a mussel adhesive protein in preparing cosmetics for skin beautifying. The application disclosed by the invention has the following main beneficial effects: 1, after a mussel adhesive protein-containing cosmetic is applied on the skin, a molecular layer is formed on the skin, and after most of moisture is evaporated, because the mussel adhesive protein has a strong pyknosis effect, the mussel adhesive protein can promote the uniform shrinkage of the skin, so that the skin forms a uniform and consistent shrinkage layer, and then the occurrence of large wrinkles is avoided, thereby achieving the effect of instant skin firming and wrinkle removal, and improving the firmness and wrinkle resilience of the skin; 2, the smoothness and glossiness of the skin are increased; 3, the action of stains is reduced; and 4, the mussel adhesive protein is non-toxic and harmless.

New synthetic Lipid-A analogs based on monosaccharide (1) and disaccharide (2) derivatives were designed and prepared in the present invention. Both structures (1) and (2) incorporate novel lipid structures (3) and (4) that are not found in nature. Also, novel disaccharide Lipid-A structures (2) that incorporate novel contingents of uniform lipids and where R₁, R₄ and R₅ are the same substitution group of structure (III) were synthesized. Liposome formulations containing totally synthetic components such as synthetic Lipid-A and synthetic lipopeptide derived from tumor-associated MUC1 mucin are described along with their therapeutic utility. Comparative test results of immunostimulating properties and toxicity of Lipid-A analogs (1) and (2) are included.

Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.

The invention discloses a method for preparing a high-purity taste-removing purple sweet potato pigment, and belongs to the field of food additives and agricultural product deep processing. The method for preparing the high-purity taste-removing purple sweet potato pigment comprises the steps that 1, pretreatment is conducted on purple sweet potato raw materials; 2, the purple sweet potato pigment is extracted from low-frequency microwave auxiliary acidified aqueous solution; 3, preliminary purification is conducted on macroporous resins; 4, high-speed counter-current chromatography separation and purification are conducted, and the taste-removing purple sweet potato pigment with concentration more than 95% is obtained. According to the method for preparing the high-purity taste-removing purple sweet potato pigment, the microwave auxiliary acidified aqueous solution is used for extraction, flocculants are added to flocculate mucoproteins, then macroporous resin static adsorption and dynamic elution are conducted, and the taste-removing and enrichment purification process is preliminarily accomplished, and the high-purity taste-removing purple sweet potato pigment is finally prepared through the high speed counter-current chromatography method in a separation mode. According to the method for preparing the high-purity taste-removing purple sweet potato pigment, technological processes are advanced, separation efficiency is high, recovery rate is high, product purity is more than 95%, preparation amount is large, an obtained product is free of peculiar smell, has few impurities and is good in solubility, and method for preparing the high-purity taste-removing purple sweet potato pigment is easy to popularize and use.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.

The invention provides a process for extracting yam mucoproteins from yams and belongs to the field of extracting functional biological macromolecular substances from natural materials to produce functional healthcare food. The extracting process comprises the main steps of (1) material selection; (2) leaching gelatinization; (3) enzymolysis; (4) standing; (5) adjustment of PH value; (6) flocculation; (7) precipitation; and (8) drying. The yield of the yam mucoprotein products prepared by the process is 4 to 5 percent, and the content of yam mucoprotein is 60 to 67 percent. According to the process provided by the invention, the organic solvent extraction in the prior art is replaced by the flocculation and natural precipitation, so the product cost is greatly saved, the environmental pollution is lowered, and the process has great significance for actual production.

The invention discloses a preparation method of saliva extracellular vesicles and application of the saliva extracellular vesicles to molecular diagnosis.The preparation method includes the steps of removing high-abundance proteins from saliva samples, filtering out mucoproteins, separating and extracting the extracellular vesicles, characterizing the obtained extracellular vesicles, extracting extracellular vesicle proteins, identifying the extracellular vesicle proteins and applying the extracellular vesicle proteins to lung cancer biomarker discovery.Currently, a normalized saliva extracellular vesicle preparation technology is absent, and high-abundance protein interference and background impurity interference, existing in existing preparation technologies, result in shortcomings of low extracellular vesicle recovery rate, fewer identified proteins and the like, so that true extracellular vesicle proteomics information can be reflected difficultly.The preparation method of the saliva extracellular vesicles and application of the saliva extracellular vesicles to molecular diagnosis have the advantages that saliva of healthy adult volunteers and lung cancer patients is taken as the samples, and an affinity chromatography and membrane separation combined technology is adopted, so that after the high-abundance proteins and the mucoproteins of the saliva are removed, the extracellular vesicles in the saliva are extracted centrifugally, proteomes of the extracellular vesicles are analyzed and more extracellular vesicle proteins are identified.

Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's can further include one or more mucins, cytokines, or growth factors. Exemplary formulations include stem cells and SRMs derived from epithelial stem cells, corneal limbal stem cells, and fibroblasts. Other compositions and methods for formulation thereof are described.

The invention discloses a method for culturing an artificial cartilage with different curved surfaces or a bone cartilage under the action of rolling load and sliding load. The method comprises an incubator which contains O2 and CO2 and can perform temperature adjustment and cell culture, perfusion and other conditions which are used for keeping culture solution fresh, and active factors which are added to the culture solution. The method is characterized in that culture blanks with different curved surfaces are fixed on the bottom plate of a culture room; during the culturing process, a culture is subjected to the effect of the rolling load and the sliding load simultaneously, and the culture is cultured into cartilage tissues or bone cartilage complex tissues. The method has the advantages that under the effect of the rolling load and the sliding load, the loading way of the method is closer to the mechanical environment of the growth and the development of the cartilage tissues; and under the loading condition, the method is favor of the growth and the development of cells and tissues. An experiment shows that mucopolysaccharide secreted by cartilage cells under the effect of the rolling load and the sliding load is higher than the mucopolysaccharide secreted by the cartilage cells only under the effect of the rolling load. After being cultured, the cultures with different shapes can be taken as implants, and the method of the invention is applied in repairing the defect of the cartilage in different parts.

The invention relates to a chimeric antigen receptor and an expression gene thereof, a double-antigen regulated type T cell modified by the chimeric antigen receptor, and application thereof. The expression gene of the chimeric antigen receptor comprises a first fusion protein expression gene and a second fusion protein expression gene, wherein the first fusion protein expression gene comprises a mucoprotein-1 antibody expression gene, a notch receptor expression gene and a Gal4-VP64 transcription activating protein expression gene which are sequentially connected; the second fusion protein expression gene comprises a Gal4-UAS promoter expression gene and an anti-mesothelin expression gene which are sequentially connected. By adopting the innovative design, the chimeric antigen receptor has the advantages that the chimeric antigen receptor can be successfully imported into the T cell to form the T cell modified by the chimeric antigen receptor; the immune reaction cannot be produced until the mucoprotein-1 and the anti-mesothelin signals simultaneously exist, so as to reach the controllable immune reaction of the chimeric antigen receptor, fewer side effects in treatment, and high specificity.

The invention relates to the technical field of mucin 1 detection, in particular to a fluorescent biological probe for mucin 1 detection, a sensor, application and a detection method. In the present invention, the aptamer probe is used for an Exo I assisted target circulation (EATR) reaction. The hairpin probe comprises a hairpin probe H1 and a hairpin probe H2 which are used for GO-assisted hybridization chain reaction (HCR); the aptamer probe and the hairpin probe are combined to be used for mucin 1 detection, so organic combination of Exo I-assisted target circulation reaction and GO-assisted hybridization chain reaction can be realized; therefore, cascade amplification of fluorescence signals is realized, the detection sensitivity of mucoprotein 1 is remarkably improved, the detectionlimit is reduced, quantitative detection of low-concentration mucin 1 can be realized, and theprobe has high specificity and can be used for specifically identifying and detecting mucin 1.

The invention discloses a method for detecting miRNA (micro ribonucleic acid) in stomach juice, which comprises stomach juice extraction and neutralization, RNA release, chloroform extraction, isopropanol precipitation, ethanol washing, RNA reverse transcription, PCR (Polymerase Chain Reaction) detection and other steps. In the detection method, a sodium hydroxide solution is used to liquefy viscous components in the stomach juice, so that mucoproteins and polysaccharides are suspended in the solution, and the stomach juice is neutralized; trypsinase is added to carry out digestion, so that the mucoproteins and other proteins can be hydrolyzed, and cell components in the stomach juice are loosened at the same time, thereby facilitating centrifugal separation; and a Trizol solution is added to carry out repeated blow and beat, so that the RNA is completely released and separated from the polysaccharides, the mucoproteins and other impurities, thereby solving the problem that the RNA extraction can be disturbed by the acidity of the stomach juice as well as polysaccharides, mucoproteins and the like in the stomach juice. Thus, the invention can eliminate the disturbance caused by polysaccharides, proteins and other impurities in the stomach juice, complete the efficient extraction of miRNA in the stomach juice and carry out fluorescent quantitative PCR detection on the extracted miRNA.

The invention relates to the use of human bendazac lysine in pharmaceutical industry, wherein the bendazac lysine possesses substantial actions for reducing hypoglycemia and saccharifying hemoglobin and urine protein, thus can be applied to the prevention and treatment of diabetes.

The invention provides a microbial composition with a weight losing effect. The microbial composition is prepared from lactobacillus gasseri and ackermansiella muciniphila, wherein the lactobacillus gasseri and the ackermansiella muciniphila are added into the microbial composition; the ratio of the viable count of the lactobacillus gasseri to the viable count of the mucophilic protein-ackermania is (2: 3)-(3: 2). By means of the probiotic composition containing lactobacillus gasseri and mucoprotein-ackermania in a specific ratio and specific content, the condition of abnormal body weight caused by metabolic diseases can be improved.